Haemonetics Stock Performance
| HAE Stock | USD 88.46 2.91 3.40% |
On a scale of 0 to 100, Haemonetics holds a performance score of 8. The company retains a Market Volatility (i.e., Beta) of 0.97, which attests to possible diversification benefits within a given portfolio. Haemonetics returns are very sensitive to returns on the market. As the market goes up or down, Haemonetics is expected to follow. Please check Haemonetics' total risk alpha, value at risk, and the relationship between the standard deviation and treynor ratio , to make a quick decision on whether Haemonetics' current trending patterns will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Haemonetics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of rather inconsistent basic indicators, Haemonetics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.92 | Five Day Return 3.89 | Year To Date Return 3.42 | Ten Year Return 135.55 | All Time Return 1.4 K |
Last Split Factor 2:1 | Last Split Date 2012-12-03 |
1 | Disposition of tradable shares by Anila Lingamneni of Haemonetics at 90.0 subject to Rule 16b-3 | 09/06/2024 |
2 | Acquisition by Laurie Miller of 2089 shares of Haemonetics subject to Rule 16b-3 | 09/13/2024 |
3 | Disposition of 238 shares by Laurie Miller of Haemonetics at 76.54 subject to Rule 16b-3 | 09/17/2024 |
4 | HAE vs. BSX Which Stock Is the Better Value Option | 09/27/2024 |
5 | Disposition of 320 shares by Josep Llorens of Haemonetics at 95.73 subject to Rule 16b-3 | 10/21/2024 |
6 | Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | 10/24/2024 |
7 | Acquisition by Stewart Strong of 6313 shares of Haemonetics at 95.73 subject to Rule 16b-3 | 11/01/2024 |
8 | Insulin Delivery Innovator PharmaSens Appoints Robert Gabbay, MD and James Peterson to Board of Directors | 11/06/2024 |
9 | Wellington Management Group LLP Increases Stake in Haemonetics Corp | 11/08/2024 |
10 | Haemonetics to lay off 75 in California facility closure | 11/12/2024 |
11 | Labcorp Adds New Capabilities to Global Trial Connect Stock to Gain | 11/13/2024 |
12 | T. Rowe Price Investment Management, Inc. Expands Stake in Haemonetics Corp | 11/14/2024 |
13 | HAE or BSX Which Is the Better Value Stock Right Now | 11/15/2024 |
14 | Reasons to Retain BSX Stock in Your Portfolio for Now | 11/19/2024 |
15 | BellRing Brands Inc. Soars to 52-Week High, Time to Cash Out | 11/20/2024 |
16 | ALGN Stock to Gain From CE Mark Win for Invisalign Palatal Expander | 11/21/2024 |
17 | MDT Stock Gains From FDA Approval for Its InPen App | 11/22/2024 |
| Begin Period Cash Flow | 284.5 M | |
| Free Cash Flow | 115.5 M |
Haemonetics |
Haemonetics Relative Risk vs. Return Landscape
If you would invest 7,669 in Haemonetics on August 27, 2024 and sell it today you would earn a total of 1,177 from holding Haemonetics or generate 15.35% return on investment over 90 days. Haemonetics is generating 0.2471% of daily returns assuming volatility of 2.2262% on return distribution over 90 days investment horizon. In other words, 19% of stocks are less volatile than Haemonetics, and above 96% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Haemonetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Haemonetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Haemonetics, and traders can use it to determine the average amount a Haemonetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.111
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HAE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.23 actual daily | 19 81% of assets are more volatile |
Expected Return
| 0.25 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Haemonetics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Haemonetics by adding it to a well-diversified portfolio.
Haemonetics Fundamentals Growth
Haemonetics Stock prices reflect investors' perceptions of the future prospects and financial health of Haemonetics, and Haemonetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Haemonetics Stock performance.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0588 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 5.22 B | ||||
| Shares Outstanding | 50.22 M | ||||
| Price To Earning | 50.35 X | ||||
| Price To Book | 4.89 X | ||||
| Price To Sales | 3.16 X | ||||
| Revenue | 1.31 B | ||||
| Gross Profit | 530.77 M | ||||
| EBITDA | 262.1 M | ||||
| Net Income | 117.56 M | ||||
| Cash And Equivalents | 284.47 M | ||||
| Cash Per Share | 4.79 X | ||||
| Total Debt | 807.79 M | ||||
| Debt To Equity | 1.12 % | ||||
| Current Ratio | 2.73 X | ||||
| Book Value Per Share | 17.44 X | ||||
| Cash Flow From Operations | 181.75 M | ||||
| Earnings Per Share | 2.41 X | ||||
| Market Capitalization | 4.3 B | ||||
| Total Asset | 2.2 B | ||||
| Retained Earnings | 360.46 M | ||||
| Working Capital | 468.52 M | ||||
| Current Asset | 488.09 M | ||||
| Current Liabilities | 185.55 M | ||||
About Haemonetics Performance
By analyzing Haemonetics' fundamental ratios, stakeholders can gain valuable insights into Haemonetics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Haemonetics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Haemonetics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 183.04 | 119.29 | |
| Return On Tangible Assets | 0.10 | 0.05 | |
| Return On Capital Employed | 0.09 | 0.07 | |
| Return On Assets | 0.05 | 0.04 | |
| Return On Equity | 0.12 | 0.06 |
Things to note about Haemonetics performance evaluation
Checking the ongoing alerts about Haemonetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Haemonetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: MDT Stock Gains From FDA Approval for Its InPen App |
- Analyzing Haemonetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Haemonetics' stock is overvalued or undervalued compared to its peers.
- Examining Haemonetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Haemonetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Haemonetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Haemonetics' stock. These opinions can provide insight into Haemonetics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |